Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide - Full Text View

Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

This study has been completed.

Sponsored by:	Sanwa Kagaku Kenkyusho Co., Ltd.
Information provided by:	Sanwa Kagaku Kenkyusho Co., Ltd.
ClinicalTrials.gov Identifier:	NCT00334503

Purpose

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

Condition	Intervention	Phase
Type 2 Diabetes Mellitus	Drug: Miglitol	Phase III

MedlinePlus related topics:

Diabetes

ChemIDplus related topics:

Miglitol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Eligibility

Ages Eligible for Study:	20 Years to 69 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 2 diabetic patients with Biguanide treatment
Criteria for postprandial plasma glucose and HbA1c are met

Exclusion Criteria:

Type 1 diabetes
Patients treated with other antidiabetic drugs or Insulin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00334503

Locations


Japan

	Hokkaido, Japan

	Ibaragi, Japan

	Gunma, Japan

	Saitama, Japan

	Chiba, Japan

	Kanagawa, Japan

	Kagoshima, Japan

	Osaka, Japan

	Fukuoka, Japan

	Kumamoto, Japan

	Oita, Japan

	Miyazaki, Japan

	Aichi, Japan

Sponsors and Collaborators

Sanwa Kagaku Kenkyusho Co., Ltd.

Investigators


Study Director:	Clinical Study Group, Clinical Development Dept.	Sanwa Kagaku Kenkyusho Co., Ltd.

More Information

Study ID Numbers:	MG1009
First Received:	June 5, 2006
Last Updated:	October 8, 2008
ClinicalTrials.gov Identifier:	NCT00334503
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanwa Kagaku Kenkyusho Co., Ltd.:

alpa-glucosidase inhibitor,Biguanide

Study placed in the following topic categories:

Miglitol

Metabolic Diseases

Diabetes Mellitus, Type 2

Diabetes Mellitus

Endocrine System Diseases

Endocrinopathy

Metabolic disorder

Glucose Metabolism Disorders

Additional relevant MeSH terms:

Hypoglycemic Agents

Molecular Mechanisms of Pharmacological Action

Physiological Effects of Drugs

Enzyme Inhibitors

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 14, 2008